Clinical, biochemical, molecular and treatment aspects of Adenosine Deaminase (ADA) deficiency

Autores: Tintos Hernández Jesús Alonso, Dávalos Rodríguez Ingrid Patricia

Resumen

Adenosine deaminase (ADA) deficiency, is a purine metabolic disorder that cause severe combined immunodeficiency (SCID) due to the accumulation of toxic metabolites that primarily affects development, differentiation and function of T and B lymphocytes. In addition, some patients show neurological, renal and liver abnormalities, delayed in development, deafness and seizures. If the immune response is not restored, children with this disorder rarely survive; therefore, ADA deficiency must be suspected when difficulty gaining weight, recurrent infections and skeletal abnormalities are present. This deficiency has clinical and immunological characteristics not seen in other immunodeficiencies, data that helps to guide the diagnosis and therapy. This review summarizes clinical, pathological, molecular and treatment findings described in this disease.

Palabras clave: Adenosine desaminase deficiency. Purine metabolism. Severe combined immunodeficiency disease (SCID).

2013-07-24   |   431 visitas   |   Evalua este artículo 0 valoraciones

Vol. 63 Núm.1. Enero-Enero 2011 Pags. 75-83 Rev Invest Clin 2011; 63(1-ENGLISH)